Published in Drug Law Weekly, August 21st, 2007
Second Quarter 2007:
- Diluted earnings per share was $0.14. Non-GAAP(1) diluted earnings per share, excluding stock-based compensation expenses, was $0.21.
- Upgrade revenue increased 84%, compared to the second quarter of 2006, due primarily to our recently-launched Pearl product.
- Cash generated by operations was $5.7 million.
First Half 2007:...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.